{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifdsgaboeif7epfbirry7cx3n2etccu5vtaeslfmtqkbtexwtzl2m",
    "uri": "at://did:plc:izotgtw5czjnuqtpcldjnkjh/app.bsky.feed.post/3mjoh2763t7x2"
  },
  "path": "/why-promising-cancer-drugs-failed-scientists-uncover-the-missing-piece/",
  "publishedAt": "2026-04-16T14:46:21.000Z",
  "site": "https://scitechdaily.com",
  "tags": [
    "Health",
    "Cancer",
    "Epigenetics",
    "Max Planck Institute",
    "Molecular Biology"
  ],
  "textContent": "A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials. For more than ten years, researchers have tested a group of cancer drugs known as BET inhibitors with high hopes. The science appeared solid. Many tumors rely on oncogenes that “Bromo- and Extra-Terminal domain” [...]",
  "title": "Why Promising Cancer Drugs Failed: Scientists Uncover the Missing Piece"
}